Inflammation  >>  Ximency (daclatasvir/asunaprevir/beclabuvir)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ximency (daclatasvir/asunaprevir/beclabuvir) / BMS
RHACE 1, NCT02098616: Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

Completed
N/A
25
US
DCV/ASV/BMS-791325, Fixed Dose Combination (FDC) of Daclatasvir/Asunaprevir/BMS-791325, DCV/ASV/BMS-791325 + RBV
Timothy Morgan, MD, VA Long Beach Healthcare System, National Cancer Institute (NCI), Bristol-Myers Squibb
Hepatitis C
02/16
02/16
NCT03071133: Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

Completed
N/A
344
Japan
Bristol-Myers Squibb
Hepatitis C
01/19
01/19

Download Options